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ABSTRACT Respiratory syncytial virus (RSV) mediates host cell entry through the fu-
sion (F) protein, which undergoes a conformational change to facilitate the merger
of viral and host lipid membrane envelopes. The RSV F protein comprises a trimer of
disulﬁde-bonded F1 and F2 subunits that is present on the virion surface in a meta-
stable prefusion state. This prefusion form is readily triggered to undergo refolding
to bring two heptad repeats (heptad repeat A [HRA] and HRB) into close proximity
to form a six-helix bundle that stabilizes the postfusion form and provides the free
energy required for membrane fusion. This process can be triggered independently
of other proteins. Here, we have performed a comprehensive analysis of a third hep-
tad repeat region, HRC (amino acids 75 to 97), an amphipathic -helix that lies at
the interface of the prefusion F trimer and is a major structural feature of the F2
subunit. We performed alanine scanning mutagenesis from Lys-75 to Met-97 and as-
sessed all mutations in transient cell culture for expression, proteolytic processing,
cell surface localization, protein conformation, and membrane fusion. Functional
characterization revealed a striking distribution of activity in which fusion-increasing
mutations localized to one side of the helical face, while fusion-decreasing muta-
tions clustered on the opposing face. Here, we propose a model in which HRC plays
a stabilizing role within the globular head for the prefusion F trimer and is poten-
tially involved in the early events of triggering, prompting fusion peptide release
and transition into the postfusion state.
IMPORTANCE RSV is recognized as the most important viral pathogen among pedi-
atric populations worldwide, yet no vaccine or widely available therapeutic treat-
ment is available. The F protein is critical for the viral replication process and is the
major target for neutralizing antibodies. Recent years have seen the development of
prefusion stabilized F protein-based approaches to vaccine design. A detailed under-
standing of the speciﬁc domains and residues that contribute to protein stability
and fusion function is fundamental to such efforts. Here, we present a comprehen-
sive mutagenesis-based study of a region of the RSV F2 subunit (amino acids 75 to
97), referred to as HRC, and propose a role for this helical region in maintaining the
delicate stability of the prefusion form.
KEYWORDS respiratory syncytial virus, fusion, membrane fusion, mutagenesis,
heptad repeat
Respiratory syncytial virus (RSV) is widely considered the most signiﬁcant viralpediatric pathogen worldwide. Belonging to the Pneumovirinae family, RSV causes
substantial morbidity and mortality worldwide, with an estimated 33.8 million acute
lower respiratory tract infections per year in children under 5 years of age, and has been
linked to almost 200,000 deaths annually, 99% of which are in developing countries (1,
2). RSV is also recognized as an important pathogen of high-risk adult and elderly
populations (3). Despite this, no targeted drug or vaccine is available, and immunopro-
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phylaxis is reserved for only a select group of high-risk infants and does not effectively
reduce disease burden (4). The fusion glycoprotein, F, is highly conserved between the
two subgroups of RSV and is the major target for neutralizing antibodies (5, 6), features
that have made the F protein the major focus of vaccine and antiviral development.
The F protein is initially expressed as a precursor (F0) that is cleaved at two sites by
a furin-like protease in the trans-Golgi network, which results in two disulﬁde-linked
subunits, F1 and F2, and releases a 27-amino-acid (aa) fragment, p27, of unknown
function (7–9). Trimerized and fully cleaved F adopts a fusion-competent, metastable
prefusion state which is found at the surface of infected cells where it is incorporated
into budding infectious virions. Anchored by a hydrophobic transmembrane domain at
its C terminus, F1 comprises the hallmark features of a type 1 fusion protein, having a
hydrophobic fusion peptide (FP) at the N terminus and two major heptad repeats, A
and B (HRA and HRB, respectively), that ultimately refold to form the hyperstable
six-helix bundle (6HB) that constitutes the fusion core of the postfusion structure.
Triggering of the protein is thought to be provoked by receptor engagement, which
prompts the release of the hydrophobic FP into the target membrane and the accom-
panied elongation of the HRA helices beyond the head of the protein (10, 11). Refolding
of HRA and HRB brings the viral and host membranes into close proximity, resulting in
membrane fusion driven by the energy difference between the pre- and postfusion
conformations of the protein (10, 11). In addition to facilitating the fusion of viral and
cellular membranes, cell surface F protein also drives fusion between infected and
neighboring cells, resulting in the formation of large multinucleated cells, or syncytia
(12, 13).
While pre- and postfusion forms of F have been crystallized, many of the speciﬁc
events that underlie the process are still unknown (14, 15). Since HRA and HRB have
been extensively studied due to their role in the formation of the critical 6HB, we
shifted our focus to a heptad repeat in the F2 subunit (aa 75 to 97), referred to herein
as HRC, which has remained largely uncharacterized in RSV. HRC is an amphipathic
-helix that lies at the interface between two protomers of the prefusion protein, with
the C terminus of the helix in close proximity to the FP (14) (Fig. 1). HRC lies adjacent
to HRA within the globular head of F in its prefusion form and also packs against a
fourth heptad repeat (aa 214 to 241), referred to herein as HRD.
To investigate this region, an alanine scan was performed throughout the helix, and
22 alanine mutations were generated in a recombinant codon-optimized F plasmid.
Transfection of this plasmid alone has previously been shown to be sufﬁcient to drive
extensive syncytium formation, providing an ideal system to assay the effect of
mutation on fusion promotion without the need for cotransfection of other viral
proteins (13). Transfected cells were assayed for F protein expression, processing, cell
surface localization, conformational state, and fusion phenotype. The results of this
analysis indicate that HRC may provide important stabilizing interactions in the glob-
ular head of the protein and suggests a critical role for HRC in the fusion process.
RESULTS
Generation of mutations in the HRC domain. In order to investigate the role of
HRC in fusion, an alanine scan was performed at each amino acid within the region of
Lys-75 to Met-97. Twenty-two mutated plasmids were generated by site-directed
mutagenesis, each containing a single alanine substitution in the codon-optimized
wild-type (WT) F sequence (based on the RSV A2 strain), with the exception of position
89, which is an alanine within the WT sequence. In the pIRES2-EGFP plasmid (Clontech),
the F sequence is immediately followed by enhanced green ﬂuorescent protein (EGFP)
under the control of an internal ribosome entry site (IRES), allowing visualization of
successfully transfected cells. The entire open reading frame for each mutation was
sequence veriﬁed and conﬁrmed to be free from polymerase-induced errors prior to
functional analysis.
Expression and proteolytic processing of F constructs. Following translation, the
F protein must undergo proteolytic processing to become fusogenic; the protein is
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initially made as an inactive F0 precursor that is cleaved at two sites by a furin-like
protease in the trans-Golgi network (site 1, RARR109; site 2, KKRKRR136). The intervening
27-amino-acid peptide, p27, is then released, allowing the remaining disulﬁde-linked
F1-F2 subunits to form the fusion-active trimer of heterodimers (8, 9). To assess the
expression and processing of F protein mutations relative to those of the WT protein,
monolayers of COS-7 cells were transiently transfected, lysed with a mild detergent
after 24 h, and assessed by SDS-PAGE and Western blot analysis (Fig. 2) using the
monoclonal antibody motavizumab that recognizes the site II epitope present in both
the 70-kDa precursor F0 and the fully cleaved 50-kDa F1 subunit (16). This allowed the
simultaneous conﬁrmation of both protein expression and proteolytic processing.
Western blot analysis revealed that the majority of mutant proteins were expressed
at levels similar to the level of WT F, with some reduction observed for the mutations
E82A, Y86A, L93A, and L96A (Fig. 2). For one mutation, Q81A, no expression was
observed either by Western blotting or immunoﬂuorescence (IF) on ﬁxed and perme-
abilized cells with anti-F polyclonal rabbit serum (data not shown). For this expression
construct, EGFP ﬂuorescence was visualized, conﬁrming efﬁcient transfection and
transcription. It is therefore likely that this mutation is not viable, with the protein likely
misfolded, retained in the endoplasmic reticulum (ER), and degraded.
Western blot analysis also allows the efﬁciency of proteolytic cleavage relative to
that of the WT F to be quantiﬁed through comparison of the ratio of cleaved F1 to its
uncleaved precursor F0. Of the 22 mutations generated, approximately half showed
some cleavage deﬁciency. This is most noticeable in E82A, L83A, V90A, L93A, and, to a
lesser extent, in Y86A and L96A, where a larger portion of the protein present is in the
70-kDa F0 form that is not cleaved at either of the two cleavage sites.
FIG 1 RSV F structure. (A) Schematic diagram of the RSV F monomer showing the two cleavage sites
(black arrows) and the resultant p27 region that is liberated from the disulﬁde-linked (s-s; solid line) F1
and F2 subunits that comprise the heterodimer. (B) F forms a trimeric prefusion structure that undergoes
conformational rearrangements to the postfusion form. Both forms have been solved by X-ray crystal-
lography (PDB accession numbers 4JHW and 3RK1) (14, 15). Two protomers are shown in two shades of
gray with surface representation, while the third is shown as a ribbon with coloring as described for panel
A. TM, transmembrane region.
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SDS-PAGE analysis of the cell lysates also revealed a degradation product of WT F of
about 20 kDa, which matches the expected size of an unpublished crystal structure of
the F head domain (PDB accession number 4CCF). This deposited fragment contains the
motavizumab epitope and, according to the description in the Protein Data Bank (PDB),
was derived as a by-product of cellular protease cleavage at some time during
expression or puriﬁcation. An alternate 30-kDa by-product corresponding to the re-
maining C terminus of F1 (as determined by Western blotting to a C-terminally bound
puriﬁcation tag) has also been observed by other investigators during recombinant F
protein expression (17). This product is absent in the cleavage-deﬁcient mutations
(E82A, L83A, V90A, and L93A) and reduced in others (Y86A and L96A). Interestingly, this
degradation product is also reduced in E92A, despite cleavage efﬁciency similar to that
of the WT.
Cell surface expression of F protein mutations. Translocation of nascent RSV F
protein to the plasma membrane is an essential step in the viral life cycle, required for
both F-mediated cell fusion and incorporation into budding virions. Flow cytometry of
transfected cells was used to assess the total levels of F protein on the cell surface
(using monoclonal antibody motavizumab; the site II epitope is available on both the
pre- and postfusion forms) and protein conformation (using the prefusion-speciﬁc
monoclonal antibody D25) (Fig. 3A).
Mutations that resulted in decreased processing (Fig. 2) were found to result in
lower cell surface expression. Mutations E82A, L83A, V90A, and L93A, all of which
showed less than 50% of WT F cleavage levels, were present on the cell surface at levels
below 50% of the level detected for WT F. Mutation Q81A was not detected on the cell
surface, consistent with this protein not being detected by Western blotting (Fig. 2).
FIG 2 Expression and processing of HRC mutations. Transiently transfected monolayers of COS-7 cells
were lysed at 24 h posttransfection (hpt) and separated by SDS-PAGE in a reducing buffer. On each gel,
positive (WT F) and negative controls (empty vector [ev]) were examined. Proteins were transferred to
nitrocellulose and probed with motavizumab (human IgG) and with GAPDH (rabbit IgG) monoclonal
antibody as a host protein control and revealed by anti-human 800 and anti-rabbit 680. Membranes were
scanned on the LiCor Odyssey Imaging System, and band intensity was measured by Image Studio
Software (LiCor) and normalized to GAPDH intensity. Cleavage efﬁciency is expressed as the intensity of
F1 divided by that of F1 plus F0. n/a, not applicable; FDEG, degradation product of WT F.
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Mutation L93A also led to the corresponding protein not being detected on the cell
surface, indicating that it was likely retained within the secretory pathway. Generally,
cleavage efﬁciency was positively correlated with cell surface expression and correct
protein conformation (Fig. 3B and C).
As motavizumab has been previously shown to bind both cleaved and uncleaved
RSV F with similar dissociation constants, quantiﬁcation of cell surface expression
should not be directly affected by processing (18). This experiment was also duplicated
and conﬁrmed with 18B2 (Argene), which targets an unknown epitope on F1 that is
exposed in both the pre- and postfusion forms (data not shown).
RSV F protein stability is a critical determinant of function. F protein must remain in a
metastable conformation to allow appropriate triggering of the conformational change
into the postfusion form. Increased stability could prevent this transition, while de-
creased stability could result in premature triggering to the postfusion form. This
transition is irreversible under physiological conditions and renders the fusion protein
inactive. Heat, low-molarity buffer, and freeze-thaw cycles have all been shown to cause
this unidirectional conformation change (17, 19, 20). Recently, a number of confor-
mation-speciﬁc antibodies have been characterized. We utilized D25, which is speciﬁc
for the prefusion structure of RSV F (14), to probe the amount of prefusion F on the cell
surface (Fig. 3A).
Of all the HRC mutations, none was found to have a signiﬁcantly higher cell
surface representation of prefusion F than the WT, indicating that none of these
mutations had the effect of stabilizing the protein in the prefusion conformation. A
number of mutations that had similar or slightly reduced levels of total F surface
expression relative to that of the WT (inferred by motavizumab binding levels)
showed signiﬁcantly reduced amounts of D25-reactive prefusion F. These include
FIG 3 Cell surface expression and conformation of transiently expressed F proteins. (A) At 24 hpt, the antibody
motavizumab was used in ﬂow cytometry to assess the level of protein expression at the cell surface. GFP
ﬂuorescence from the pIRES2-EGFP vector was used to gate successfully transfected cells and the monoclonal
antibodies motavizumab and prefusion-speciﬁc D25 used to quantify F protein expression. The average median
ﬂuorescence intensity (MFI) of three independent replicates is shown relative to that of the WT F  standard error
of the mean. The log-transformed surface expression levels of total F bound by motavizumab (B) and prefusion F
bound by D25 (C) are plotted against cleavage efﬁciency. Both surface expression and cleavage efﬁciency values
are presented relative to the levels of the WT F, with linear regression used to model the relationship.
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K75A, L78A, and I79A. Most dramatically, I79A, which had 68% of the WT level of
total F surface expression (as detected by motavizumab), had only 4% of the level
of WT prefusion F surface expression (as detected by D25). A similar trend was
observed for mutations K77A, L78A, and Y86A although to a lesser extent. Cell
surface representation of less than 10% of WT F prefusion was also true of the
processing-deﬁcient mutations that had low levels of total F, speciﬁcally, E82A,
L83A, Y86A, V90A, L93A, and L96A.
Fusogenicity and helical localization. After expression, processing, and cell sur-
face conformation were conﬁrmed, all mutations were functionally assessed on their
ability to drive cell fusion through both direct visualization and a quantitative electrical
impedance-based fusion assay, a previously described method that detects syncytium
formation through a decrease in electrical impedance across a cell monolayer (21). For
direct visualization, monolayers of COS-7 cells were transiently transfected with mu-
tated and control plasmids that coexpressed GFP under an internal ribosomal entry site.
Fusion was visually graded on the extent of GFP diffusion caused by F-mediated
cell-cell fusion and the subsequent cell content mixing (22). Almost all mutations were
observed to have some effect on syncytium formation, with a range of phenotypes
being observed, ranging from complete abrogation of fusion to WT levels. For some
mutations, an increase over and above WT F levels was seen. Fusion phenotype was
scored based on both the number of syncytia observed as well as the size of any
syncytia present (Fig. 4B) and further quantiﬁed with an electrical impedance fusion
assay (Fig. 4A).
The results of both assays were largely consistent; however, each assay had partic-
ular advantages and limitations. The impedance assay was particularly useful in quan-
tifying the increases in fusion above the level of WT F that were difﬁcult to visually rate.
Conversely, direct visualization was advantageous for observing smaller fusion events
that were below the sensitivity of the cell impedance system. Both assays were
considered for assessment of the fusion phenotype.
To visualize the effects of our site-directed mutations on fusion phenotype, we
projected the fusion phenotype onto the prefusion structure of RSV F using a color
spectrum to represent the extent of fusion (Fig. 5A and B). This revealed a striking
correspondence between amino acid position and fusion phenotype, where mutations
that were observed to decrease or completely ablate fusion were found localized to
one face of the HRC -helix while those that increased fusion were found on the
opposing face. This is particularly evident along the longitudinal axis of the helix (Fig.
5B, inset).
Ablation of fusion activity for mutations Q81A and L93A was anticipated as these
mutations were either not expressed (Q81A) or not translocated to the plasma mem-
brane (L93A) where the protein mediates cell-cell fusion. Likewise, the mutations E82A,
L83A, Y86A, V90A, and L96A all lacked any syncytium formation, likely a reﬂection of
their low cleavage efﬁciencies and reduced translocation to the cell surface. These
results are in line with previous ﬁndings, whereby proteolytic processing and cell
surface localization have been shown to be critical in F-mediated membrane fusion (8).
Interestingly, two mutations (I79A and E92A) resulted in the absence of fusion for
expressed F, even though the levels of processing and cell surface localization were
similar to those of WT F. When the relative levels of total F to those of the prefusion
conformation were compared, the relative representation of prefusion F for the I79A
protein is greatly reduced while for E92A the ratio is similar to that of the WT. These
results likely indicate two distinct mechanisms responsible for fusion ablation: de-
creased stability of the prefusion conformation leading to premature transition to the
postfusion conformation (I79A) and an inability to trigger the conformational change
into the postfusion form despite the presence of the prefusion conformation (E92A).
Five mutations showed decreased levels of fusion. Of note, four of the ﬁve were
lysine residues (K75A, K77A, K85A, and K87A), and the ﬁfth was leucine (L78A). Finally,
V76A, D84A, N88A, T91A, L95A, and M97A were all seen to increase fusion above the
Bermingham et al. Journal of Virology
February 2018 Volume 92 Issue 4 e01323-17 jvi.asm.org 6
 o
n
 August 1, 2018 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
level of the WT F. These residues all cluster to one face of the helix and are solvent
exposed. Of these six mutations, only D84A had reduced representation of F on the cell
surface and an even lower representation of the prefusion form. However, D84A was
the most fusogenic construct of all mutations analyzed, despite a large decrease in cell
surface expression.
DISCUSSION
RSV F plays a central role in viral replication and pathogenesis as a mediator of both
receptor binding and membrane fusion and as the primary target of the host’s
protective antibody response. To date, the majority of research into the fusion function
of RSV F has been focused on regions within the F1 subunit, in particular, the HRA and
HRB coiled coil (23–25). While these studies have provided deeper insight into forma-
tion and antiviral targeting of the terminal 6HB fusion core (26), the roles of residues
and domains within the F2 subunit remain relatively unexplored. Here, we performed
a comprehensive mutational analysis of the HRC -helix (Lys-75 to Met-97) and
demonstrated that the region has an important role in RSV F-mediated membrane
FIG 4 Two fusion assays that measure syncytium spread in transiently transfected COS-7 cells show distinct fusion-increasing and
fusion-decreasing phenotypes. (A) Cell-cell fusion was measured by an electrical impedance fusion assay (21). At 20 hpt, impedance was
recorded and normalized to the levels of the WT F and empty vector controls. Data are the averages  standard errors of the means of
two repeats (n  3). Using the pIRES2-EGFP vector, fusion was measured by observing EGFP ﬂuorescence after images (n  5) were
captured at 24 hpt using an IN Cell Analyzer. A visual rating system for fusion phenotype was developed to score mutations against the
empty vector (ev; ) and WT F () for number and extent of syncytia, with an example for each rating shown in panel B.
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FIG 5 Localization of HRC mutations in the prefusion F structure. (A) A heptad repeat schematic showing
the HRC residues in positions a to g, with the hydrophobic face highlighted (gray). (B and C) HRC is shown
as a ribbon against the cognate (light gray) and opposing (dark gray) protomers in the prefusion
(Continued on next page)
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fusion. Each mutation was assessed for expression level, proteolytic processing, surface
expression, conformational state, and fusion activity. Of particular interest, we noted a
functional asymmetry across the region, where fusion-increasing mutations localized to
the solvent-exposed face of the HRC helix and fusion-decreasing and ablating muta-
tions located to residues on the side of the helix that is buried in the F protein structure.
Of the fusion-decreasing and -ablating mutations we have identiﬁed in RSV F, a
number showed a reduction in levels of proteolytic processing and cell surface expres-
sion. Such deﬁciencies prevent a full assessment of the direct role these residues may
play in the fusion process as both proteolytic cleavage and cell surface expression are
critical for F protein-mediated membrane fusion. Changes to the HRC (aa 75 to 97)
region could be expected to affect processing as it is located N-terminal to the ﬁrst
cleavage site between amino acids 109 and 110. While there are currently no crystal
structures of RSV F in its uncleaved state, it has previously been shown that the F
protein is likely monomeric prior to cleavage and p27 removal (18, 27). Changes in side
chain packing may alter helical positioning within monomeric F, thereby affecting
presentation of cleavage sites to the required protease(s).
Our ﬁndings also indicate that the buried residues of HRC (Gln-81, Leu-83, Tyr-86,
Val-90, Leu-93, and Leu-96) appear to play an important role in the structural integrity
of the protein, where alteration leads to a dramatic reduction in proteolytic processing
and export to the cellular membrane. Of note, a clear trend was established linking
proteolytic processing and transport to the cellular membrane. It is likely that muta-
tions resulting in protein misfolding are retained in the ER and therefore not processed
within the Golgi apparatus.
Of the paramyxo- and pneumovirus fusion proteins, RSV and human metapneumo-
virus F proteins are unique in that they are able to mediate membrane fusion in the
absence of other viral proteins (13, 28). As such, RSV F is able to maintain a functionally
active metastable state without the aid of additional viral glycoproteins. In this state,
the protein must maintain a state of delicate equilibrium that is both sufﬁciently
unstable to undergo the rapid conformational change from the pre- to the postfusion
form while also maintaining enough structural integrity to stay in the prefusion state
without premature triggering. Transition to the postfusion form in the absence of a
target membrane is irreversible and therefore renders the F protein inactive. If all F
proteins (or an amount beyond a certain threshold) on a virion are prematurely
triggered, that virus is essentially noninfectious.
Viewed within this context, our ﬁndings suggest that many of the residues within
HRC appear to play a role in conformational stability. Mutations of residues at the N
terminus of HRC (K75A, K77A, L78A, and I79A) likely have the effect of destabilizing F,
which is reﬂected in the relatively low abundance of prefusion F at the surface, despite
no signiﬁcant decrease in the total levels of F surface expression compared to the WT
protein level. N-terminal residues form a network of hydrophobic interactions near the
apex of the RSV prefusion trimer alongside residues in HRA and the ﬂexible loop
between HRA and HRD, another heptad repeat in F1 from Ile-214 to Ala-241. Substi-
tution with the smaller side chain of alanine may disrupt the packing of these helices
in the head region and possibly lead to premature rearrangement of the HRA helices
and release of the hydrophobic FP. Flexibility within this region is also evident when the
atomic structures of the stabilized prefusion F constructs (e.g., PDB accession numbers
FIG 5 Legend (Continued)
structure (PDB accession numbers 4JHW in panel B and 5K6C in panel C). Mutations that ablated fusion
(red, rating ), dramatically reduced fusion (orange, rating ), or increased fusion (light green, rating
 , or dark green, rating  ) have been color coded to reﬂect phenotype and are shown
in stick representation (B). In the inset, the helix is shown in isolation viewed from the N (foreground) to
C (back) terminus, and it is evident that mutations cluster to opposing faces relative to each phenotype.
At the N terminus of HRC, shown in panel C (in coral) against a surface representation of the protomers,
two lysine residues (Lys-75 and Lys-77) lie against a bed of negative charge from HRD residues. Basic
amino acids are shown in red while acidic residues are shown in blue. In panels B and C, a small region
of the ﬂexible loop N-terminal to HRC has been hidden to avoid obstructing the view of the helix.
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5K6C and 4MMT) are compared (data not shown) and is also apparent from the
reported crystal structure B-factors that are consistent with a high intrinsic atomic
mobility around the apex of the prefusion head, in particular the N-terminal region of
HRC (29, 30).
Also at the N terminus of HRC are two lysine residues, Lys-75 and Lys-77, alanine
substitution of which resulted in a decrease in fusion. In addition to the hydrophobic
belt discussed above, these charged residues may facilitate additional stabilizing
contacts between interprotomer HRC and HRD through electrostatic interactions with
Glu-218 and Glu-222, respectively, and may provide additional conformational stability
(Fig. 5C). Again, the localized conformation of this region is altered in the various reported
prefusion crystal structures. Both K75A and K77A mutations show a decrease in the
prefusion protein level on the cell surface, relative to the WT level, suggesting that
disruption of these potential interactions promotes destabilization in the region and
premature conformational triggering.
Another mutation of interest that ablated fusogenicity was E92A, even though it
showed WT levels of processing and cell surface representation, including the presence
of the prefusion conformation. The side chains of the glutamic acid are close enough
to hydrogen bond with Ser-238 in the HRD helix of the prefusion structure. However,
the alanine substitution does not seem to induce any destabilization since E92A shows
WT levels of the prefusion conformation F on the cell surface. Interestingly, an E92D
change was one of six mutations previously used in combination to generate a stabilized
prefusion F, though the authors of that study hypothesized that the native glutamic
acid was unfavorable due to clashes with Asn-254 in the prefusion conformation (30).
It is possible that side chain packing at this site is important during the early stages of
triggering and refolding that cannot be mediated by the small, nonpolar alanine.
Our results also suggest that the levels of expression, processing, and cell surface
expression and the relative presence of the prefusion protein conformation are not
always predictive of fusogenicity. For example, despite showing similar phenotypic
levels for each of these parameters tested, E92A completely ablated fusion while L95A
led to a slight increase. For the fusion-increasing mutations (V76A, D84A, N88A T91A,
L95A, and M97A), there does not seem to be a trend in interactions made in the static
structures of the pre- and postfusion forms of RSV F although this face of the helix is
somewhat solvent exposed. Thus, we hypothesize that these residues may play a role
during the transitional rearrangements in F and may make ﬂeeting interactions that
contribute to the thermodynamics of refolding. Removal of these side chains by alanine
mutagenesis may reduce the mechanical energy of conformational change, leading to
a more favorable transition into the postfusion form. This is seen as an increase in
fusogenicity as measured by syncytium spread. In contrast, excess instability could lead
to complete misfolding and degradation, as is likely with Q81A, which is not expressed
at all.
Our results point to a stabilizing role for many residues at the N terminus of the
helix. Leu-78 and Ile-79 contribute to a hydrophobic belt that lines the inner cavity of
the prefusion F trimer, while Lys-75 and Lys-77 facilitate trimer stabilization through
electrostatic interactions with the HRD helix in the adjacent protomer. Disruption of any
of these residues had the effect of destabilizing the protein, as seen by a reduced
detection of the prefusion form by ﬂow cytometry and a corresponding reduction in
fusion. Increased ﬂexibility in this region could potentiate premature triggering, with
HRC playing a critical role in the initiation of the pre-to-postfusion transition. Of interest, a
recent study showed that the N-terminal region of HRC in parainﬂuenza virus 5 (PIV5)
is among the ﬁrst sections of the protein head to move in the prefusion structure along
with the fusion peptide, indicating that HRC movement may be one of the earliest
events in the fusion process (31). These ﬁndings, in combination with results presented
here, may point to a conserved role for this helix across the Paramyxoviridae family.
Supporting this hypothesis, efforts to engineer a stabilized prefusion F have been
achieved in one study through limiting mobility of the ﬂexible loop immediately
N-terminal to HRC by an N67I mutation. This mutation was proposed to increase
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hydrophobic interactions between the loop, HRC, and part of HRA and effectively “stick”
this loop to these domains. Another mutation at position 215 acted to reduce repulsion
forces in this apex region where the HRA, HRD, and HRC helices meet (27).
Conversely, an F2 mutant identiﬁed in a live attenuated vaccine strain was shown
to increase syncytium formation in transfected cells and in in vitro infection with
whole virus (32). This raises the interesting question of the tolerance of fusion
protein mutations in the context of infectious virus, especially in relation to our
fusion-increasing mutations. This study and others have seen the fusogenicity of
transfected F mutations mimic the same phenotype when they are part of an
infectious virus (32, 33). Even though many of our mutations show an increase in
the fusion phenotype, the amino acid sequence of HRC is genetically stable,
suggesting that the area does not tolerate change. In the context of transfected F
protein in cell monolayers, some instability in the protein can be beneﬁcial for
syncytium spread since the target membrane is present once the protein reaches
the cell surface, and an easier transition into the postfusion form will simply lead to
larger syncytia. However, circulating virus is faced with the challenge of withhold-
ing transition until an appropriate host cell membrane is available. Correlation has
been found between an increase in fusion activity and higher viral load and
pathogenesis in mice for both RSV (33) and other paramyxoviruses (34). Thus,
circulating virus faces competing selective pressures of balancing the infectious
half-life of transmitted virions and fusion capacity.
In conclusion, we have shown that the HRC region of RSV F plays a critical role in
both protein metastability and fusion activity. Minor changes in the sequence of this
helix had a range of destabilizing effects, from abrogation of fusion activity to slight
decreases or, indeed, increases in fusogenicity. This is the most comprehensive study of
this region in the F2 subunit in RSV and, together with ﬁndings from closely related
paramyxoviruses, suggests a likely stabilizing role for this helix in the globular head of
the prefusion F trimer and potential involvement in the early events of triggering.
Stabilization of the prefusion conformation of the F protein has been a focus of recent
research as antibodies to the prefusion protein account for the majority of the neu-
tralizing antibody response (35). In this study, we have provided a functional and
biophysical analysis of putative interactions within the globular head, particularly
between HRC and HRD residues, which could be used to inform future vaccine design.
Additionally, as has been demonstrated for a closely related paramyxovirus fusion
protein (36), compounds able to prematurely trigger the fusion process can render
viruses noninfective. Understanding the domains involved in triggering of the fusion
process may also facilitate the rational design of antiviral therapeutics.
MATERIALS AND METHODS
Cells and transfection. COS-7 cells were maintained in Opti-MEM I reduced serum medium (Gibco)
supplemented with 3% fetal bovine serum (FBS) and maintained in a humidiﬁed incubator at 37°C with
5% CO2. For transfection, monolayers were seeded 1 day before transfection in Opti-MEM supplemented
with 2% FBS. DNA for transfection was mixed in a 1:4 ratio of 1 mg/ml polyethylenimine in MOPS
[3-(N-morpholino)propanesulfonic acid] buffer at pH 7 in serum-free Opti-MEM, incubated at room
temperature (RT) for 15 min, and then added to wells with sufﬁcient medium to cover the monolayer.
At 5 h posttransfection (hpt), cells were washed with phosphate-buffered saline (PBS) and then
supplemented with Opti-MEM (2% FBS).
Antibody cloning, expression, and puriﬁcation. The variable regions of motavizumab and D25
antibodies were cloned and expressed in recombinant form. Brieﬂy, the variable domains of the
antibodies were cloned into separate plasmids encoding the heavy- and light-chain human IgG back-
bones described by Jones et al. (37). Vectors were transfected into CHO cells in suspension culture, and
supernatant was harvested 7 days later for secreted antibody, which was puriﬁed by protein A
chromatography and buffer exchanged into PBS as previously described (38).
Plasmids and PCR mutagenesis. Codon-optimized RSV F (Fopt.FL) developed by Morton et al. was
subcloned into the pIRES2-EGFP vector (Clontech) using the BamHI and PstI restriction sites and used as
the template DNA in single-step site-directed mutagenesis PCR (13). Primers were designed as described
by Zheng et al., and successful mutation was conﬁrmed by Sanger sequencing at the Australian Genome
Research Facility (39). The entire coding sequence of F for each mutation was screened to ensure that
the gene was free of polymerase-induced errors. All primers are described in Table 1.
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Western blot analysis. Subconﬂuent monolayers of COS-7 cells in six-well plates (Nunc) were
transiently transfected with 1 g of mutated or control pIRES2-EGFP.Fopt plasmids. At 24 hpt cells were
scraped and then centrifuged at 1,000 rpm for 2 min at 4°C. Pellets were resuspended in 50 l of
membrane lysis buffer (10 mM Tris-HCl, pH 7.2, 0.5 M NaCl, 0.5% NP-40) with cOmplete Mini EDTA-free
protease inhibitor cocktail (Sigma-Aldrich) for 20 min on ice. Lysate was centrifuged at 10,000  g for 10
min at 4°C, and then the supernatant was boiled for 4 min with 4 SDS-PAGE loading buffer and a 1:100
dilution of 2-mercaptoethanol. Samples were run on a 4% stacking, 10% resolving SDS-PAGE gel for 10
min at 100 V and then for 1 h at 170 V. Proteins were transferred to nitrocellulose and then blocked
overnight in PBS-TMP (0.05% Tween 20, 3% skim milk powder). Membranes were incubated with human
motavizumab (1:1,000) and rabbit anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cell Sig-
naling Technology) (1:1,000) for 1 h at RT, washed three times, incubated with goat anti-rabbit 680 and
goat anti-human 800 (1:5,000) (LiCor), washed three times again, and read on a LiCor Odyssey Imaging
System.
Flow cytometry. The night before transfection, COS-7 cells were seeded into six-well plates (Nunc)
at a density of 104 cells/well in Opti-MEM (2% FBS) (Gibco). This concentration was chosen to prevent
fusion occurring between neighboring cells, which was observed at higher densities. At 24 hpt, cells were
harvested and probed with a 1:500 dilution of 18B2 (Argene), D25, or motavizumab (1 mg/ml stock) and
revealed by a 1:1,000 dilution of anti-mouse IgG1 or anti-human IgG Alexa-647 (Thermo Fisher Scientiﬁc).
Samples were read on an Accuri C6 ﬂow cytometer (Becton Dickinson Biosciences) and analyzed in
FlowJo, version 10.1 (Tree Star). Three biological replicates were performed, and results are presented as
the means  standard deviations.
Cell-cell fusion assay. COS-7 cells were seeded into a 24-well plate (Nunc) at a concentration of 105
cells/well and transfected the next day with 500 ng of DNA using the pIRES2-EGFP plasmid constructs.
After transfection, cells were washed with PBS and supplemented with 2% FBS and Opti-MEM. Live cells
were imaged at 24 hpt with an IN Cell 1000 instrument (GE Life Sciences) at a magniﬁcation of10 using
bright-ﬁeld microscopy and ﬂuorescence microscopy with 485-nm excitation and 535-nm emission ﬁlters
to detect EGFP. At 24 hpt syncytium formation was visualized through the expression of EGFP and
visually assessed based on syncytium number and size relative to numbers and sizes for the positive
(pIRES2-EGFP.Fopt) and negative (pIRES2-EGFP empty vector) controls.
Cell impedance assay. We have recently described a label-free system to measure viral fusion
through changes in electrical impedance across a cell monolayer (21). One night prior to transfection,
2  105 COS-7 cells were seeded into 12-well plates (Nunc) and transfected with 1 g of DNA the
following day. At 4 hpt, transfection medium was removed, and monolayers were washed with PBS,
removed with trypsin-EDTA solution (Thermo Fisher Scientiﬁc), and transferred to a 96-well E-plate (ACEA
Biosciences) at 4  104 cells/well. The E-plate was placed in an xCELLigence RTCA SP (real-time cell
analysis, single plate) station (ACEA Biosciences), and electrical impedance was measured and recorded
every 15 min for 72 h. Prior to cell replating, the system was blanked with Opti-MEM (2% FBS).
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TABLE 1 List of primers used for mutagenesisa
Mutation Forward primer Reverse primer
K75A GACGCCGCAGTGAAGCTGATCAAG TCACTGCGGCGTCGGTGCCGTT
V76A GCCAAGGCAAAGCTGATCAAGCAAG GCTTTGCCTTGGCGTCGGT
K77A AAGGTGGCACTGATCAAGCAAGAGCT TCAGTGCCACCTTGGCGTC
L78A GTGAAGGCAATCAAGCAAGAGCTG TGATTGCCTTCACCTTGGCGTC
I79A AAGCTGGCAAAGCAAGAGCTGG GCTTTGCCAGCTTCACCTTGGC
K80A CTGATCGCACAAGAGCTGGAC CTTGTGCGATCAGCTTCACCTTGG
Q81A ATCAAGGCAGAGCTGGACAAGTAC GCTCTGCCTTGATCAGCTTCAC
E82A CAAGCAAGCACTGGACAAGTAC CCAGTGCTTGCTTGATCAGC
L83A CAAGAGGCAGACAAGTACAAGAAC TGTCTGCCTCTTGCTTGATCAG
D84A GAGCTGGCAAAGTACAAGAACG ACTTTGCCAGCTCTTGCTTG
K85A CTGGACGCATACAAGAACGCCGTG TGTATGCGTCCAGCTCTTGCTTG
Y86A GACAAGGCAAAGAACGCCGTGACCG TCTTTGCCTTGTCCAGCTCTTGC
K87A TACGCAAACGCCGTGACCG GCGTTTGCGTACTTGTCCAGCTC
N88A GTACAAGGCAGCCGTGACC CGGCTGCCTTGTACTTGTCCAG
V90A AACGCCGCAACCGAGCTGCAAC CGGTTGCGGCGTTCTTGTACTTGTC
T91A CGTGGCAGAGCTGCAACT GCTCTGCCACGGCGTTCTTGTA
E92A GTGACCGCACTGCAACTGCTGATG GTTGCAGTGCGGTCACGGCGTTC
L93A ACCGAGGCACAACTGCTGATGC AGTTGTGCCTCGGTCACG
Q94A GAGCTGGCACTGCTGATGC CAGCAGTGCCAGCTCGGTCA
L95A GCAAGCACTGATGCAGTCG TCAGTGCTTGCAGCTCGGTC
L96A CAACTGGCAATGCAGTCGACTCAA GCATTGCCAGTTGCAGCTCGGT
M97A CTGCTGGCACAGTCGACTCA ACTGTGCCAGCAGTTGCAGC
aAlanine substitutions are underlined.
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